MIA

Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstrom's Macroglobulinemia

Data presented at the 11th International Myeloma Workshop held inKos, Greece demonstrates clinical activity of perifosine incombination with bortezomib, dexamethasone and lenalidomide plusdexamethasone, in patients with relapsed/refractory multiplemyeloma, and as a single agent in patients with relapsed/refractoryWaldenstrom's macroglobulinemia NEW YORK, June 29, 2007 /PRNewswire-FirstCal...

Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia

PALO ALTO, Calif.--(BUSINESS WIRE)--Jun 25, 2007 - Affymax, Inc.(Nasdaq:AFFY) today announced that additional Phase 2 clinicaltrial results for Hematide(TM) were presented at the European RenalAssociation-EDTA Congress being held in Barcelona, Spain by Iain C.Macdougall, M.D., a Hematide investigator from Kings College,London. Dr. Macdougall's poster included data in previously-treateddialy...

AMIA Announces 2008 Summit on Translational Bioinformatics

Program to address a broad range of topics coveringresearch-related issues and best practices in bioinformatics andcomputational biology BETHESDA, Md., June 21, 2007 /PRNewswire-USNewswire/ -- TheAmerican Medical Informatics Association (AMIA) Board of Directors,in support of its strategic plan, has approved the development ofan annual meeting that will explore topics related to translati...

Santaris Pharma Presents Positive Clinical Data on SPC2996 in Chronic Lymphocytic Leukaemia

First RNA Antagonist Medicine to Be Tested in Patients ReducesSeverity of Adult Leukaemia Copenhagen, 6th June 2007 - Santaris Pharma, the Danishbiopharmaceutical company, announced today that SPC2996, theCompany's new RNA Antagonist of Bcl-2, has shown early evidence ofefficacy in an initial Phase I/II clinical study in ChronicLymphocytic Leukaemia (CLL). The results of the study...

Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Society's Annual Meeting

SAN DIEGO--(BUSINESS WIRE)--Jun 6, 2007 - Metabasis Therapeutics,Inc. (Nasdaq:MBRX), a biopharmaceutical company focused on thediscovery, development and commercialization of novel drugs for thetreatment of metabolic and liver diseases by applying uniquecapabilities for targeting the liver and liver pathways, announcedtoday that two posters were presented at the Endocrine Society's89th Annu...

Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas

SAN CARLOS, Calif., June 05, 2007 /PRNewswire-FirstCall/ --Nuvelo, Inc. today announced the publication of data from apreclinical study of novel monoclonal antibodies against thecell-surface protein NTB-A. The data demonstrate that NTB-A is apotential new target for immunotherapy of B-cell malignanciesincluding leukemia and lymphomas. The study, entitled "The lymphoidcell surface recepto...

Dasatinib Shows High Early Response Rate as First Treatment for Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report

CHICAGO, June 2, 2007 - An established second-linedrug for chronic myelogenous leukemia has high response rates whengiven to newly diagnosed patients as their first therapy for thedisease, according to early results from a Phase II clinical trialat The University of Texas M. D. Anderson Cancer Center. "Patients taking dasatinib achieve complete cytogenetic response- absence of the...

Soliris Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes

- Analysis of Phase III Data Presented at ASCO - CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Investigatorsreported today that Soliris(TM) (eculizumab), a new treatment forparoxysmal nocturnal hemoglobinuria (PNH) developed by AlexionPharmaceuticals, Inc. , is effective in patients diagnosed with PNHwho have a history of aplastic anemia (AA) or myelodysplasticsyndromes (MDS). Soliris...

Hyperthermia Plus Chemotherapy Nearly Doubles Disease-Free Survival Compared to Chemotherapy Alone for Sarcoma Cancer Patients

SALT LAKE CITY, June 04, 2007 /PRNewswire-FirstCall/ -- BSDMedical Corp. announced today that the results of a 340 patientrandomized Phase III clinical trial testing the benefit of addinghyperthermia therapy to chemotherapy were presented at the annualAmerican Society of Clinical Oncology (ASCO) conference underway inChicago, Illinois. According to the results of this clinical study,whic...

Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia

- Results from a Children's Oncology Group (COG) Study Presented atAmerican Society of Clinical Oncology Annual Meeting - CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Immunomedics,Inc. , a biopharmaceutical company focused on developing monoclonalantibodies to treat cancer and other serious diseases, todayannounced that treatment with epratuzumab plus standardchemotherapy is feasible...

ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia

SEATTLE, June 04, 2007 /PRNewswire-FirstCall/ -- ZymoGenetics,Inc. today announced that interim findings were presented from aPhase 1b clinical trial with atacicept in B-cell chroniclymphocytic leukemia (B-CLL) at the American Society of ClinicalOncology (ASCO) 2007 annual meeting. The study included intravenousadministration of higher doses than had been tested in previousstudies. <...

Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS 301012 in Familial Hypercholesterolemia Patients

* Treatment with ISIS 301012 produced at least 45% additionalreduction in patients' LDL-cholesterol when added tomaximally-tolerated lipid-lowering therapies CARLSBAD, Calif., May 17, 2007 /PRNewswire-FirstCall/ -- IsisPharmaceuticals, Inc. announced updated results from its ongoingPhase 2 clinical trial of ISIS 301012 in patients with homozygousfamilial hypercholesterolemia (HoFH), initi...

Researchers Urge Caution in Using ESAs for Cancer-Related Anemia

Drugs Might Increase Risk of Tumor Growth, Data Suggest DURHAM, N.C., April 30, 2007 /PRNewswire/ -- Echoing recent FDAwarnings, a research group from Northern Ireland cautions againstover-aggressive use of a group of drugs called"erythropoiesis-stimulating agents" (ESAs) to treat anemia in somecancer patients, according to a commentary in the April issue ofThe Oncologist, published by Al...

Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP Phase II Trial

SYDNEY, Australia, April 26, 2007 /PRNewswire-FirstCall/ --Australian drug development company Alchemia Limited todayannounced preliminary results from its randomised Phase II clinicaltrial in patients with metastatic colorectal cancer, whereAlchemia's drug HyCAMP(TM) was compared to irinotecan which isconsidered to be a cornerstone drug for the treatment of colorectalcancer. This announ...

Prospective Model Outlined Potential Time and Cost Savings of Once-Monthly Anemia Treatment

DALLAS, Texas and NUTLEY, N.J., April 23, 2007 /PRNewswire/ --An activity-based cost analysis demonstrated that if a renal anemiatreatment administered once every four weeks replaced thrice weeklyadministration of epoetin alfa, hemodialysis centers may save anestimated 802 nursing hours and more than $44,000 per year per 100patients. These data, from a multi-center prospective analysis of...

Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month Hematide for the Treatment of Anemia in Patients with Early- and End-Stage Chronic Kidney Disease

PALO ALTO, Calif.--(BUSINESS WIRE)--Apr 23, 2007 - Affymax, Inc.(Nasdaq:AFFY) today announced results to date from two separatePhase 2 clinical trials of Hematide(TM) in dialysis andnon-dialysis chronic kidney disease (CKD) patients. The data showedthat in treatment naive, non-dialysis patients Hematide couldcorrect anemia when administered monthly at an appropriate dose.Similarly, the data...

Data Analyses Outline Efficacy and Safety of Mircera for the Treatment of Renal Anemia Associated With Chronic Kidney Disease

ORLANDO, Fla. and NUTLEY, N.J., April 12, 2007/PRNewswire-FirstCall/ -- Data analyses from the largest initialregistration clinical trial program ever undertaken in the renalanemia arena provide efficacy and safety information on theinvestigational anemia therapy MIRCERA(TM) for the treatment ofrenal anemia associated with chronic kidney disease (CKD) inpatients on dialysis and not on di...

Affymax Announces Results From Phase 2 Clinical Trial of Hematide for the Treatment of Anemia in Dialysis Patients

PALO ALTO, Calif.--(BUSINESS WIRE)--Apr 12, 2007 - Affymax, Inc.(Nasdaq:AFFY) today announced that results available from its Phase2 clinical trial of Hematide(TM) dosed monthly in dialysis patientswere presented this week at the National Kidney Foundation (NKF)2007 Spring Clinical Meeting. The results from thismaintenance-switch trial in patients previously treated withthree-times weekly E...

Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012 in Familial Hypercholesterolemia Patients Presented at ACC

* Homozygous FH patients already being treated with maximallytolerated lipid-lowering therapies experienced 50% furtherreductions in LDL-C with similar reductions in other atherogenicwhen treated with 300 mg/week ISIS 301012 NEW ORLEANS, and CARLSBAD, Calif., March 26, 2007/PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. announcedresults from its ongoing Phase 2 clinical trial of ISIS...

Studies Show Mild Hyperthermia Enhances Antitumor Effects of Alfacell's Onconase

BLOOMFIELD, N.J., March 22, 2007 /PRNewswire-FirstCall/ --Alfacell Corporation today reported that in vitro studies show mildhyperthermia enhances the therapeutic effects of ONCONASE(ranpirnase), the company's lead investigational drugcandidate. In a paper entitled, "Mild hyperthermia predisposes tumor cellsto undergo apoptosis upon treatment with ONCONASE," published inthe Intern...

Major Gene Study Uncovers Secrets of Leukemia

St. Jude Study Scans 350,000 Locations Across the Genome From 242Patients and Identifies New Mutations That Contribute to AcuteLymphoblastic Leukemia, Suggesting New Targets for Improved Therapy MEMPHIS, Tenn., March 07, 2007 /PRNewswire/ -- Investigators atSt. Jude Children's Research Hospital have discovered previouslyunsuspected mutations that contribute to the formation of pediatricac...